Cardiomyocyte S1P 1 receptor-mediated extracellular signal-related kinase signaling and desensitization

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 6, 2009, Pages 486-494

  Tao, Rong ^a,b   Hoover, Holly E ^a   Zhang, Jianqing ^a   Honbo, Norman ^a   Alano, Conrad C ^c   Karliner, Joel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adult cardiomyocytes; Desensitization; ERK; Receptor recycling; S1P receptors; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; CARDIOVASCULAR AGENT; CAY10444; FINGOLIMOD; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C EPSILON; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; DRUG DERIVATIVE; LYSOPHOSPHOLIPID; PROTEIN KINASE C; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL ISOLATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; ENZYME ACTIVATION; HEART MUSCLE; HEART PROTECTION; HYPOXIA; INCUBATION TIME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECYCLING; REOXYGENATION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HEART MUSCLE CELL; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CELL DEATH; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 68249121132     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181a7b58a     Document Type: Article

References (60)

1. Maceyka M, Payne SG, Milstien S, et al. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002; 1585:193-201.
2. Saba JD, Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res. 2004;94:724-734.
3. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4:397-407.
4. Hla T, Lee MJ, Ancellin N, et al. Lysophospholipid-receptor revelations. Science. 2001;294:1875-1878.
5. Usui S, Sugimoto N, Takuwa N, et al. Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5. J Biol Chem. 2004;279:12300-12311. (Pubitemid 38445796)
6. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J. 2000;349:385-402. (Pubitemid 30465772)
7. Bünemann M, Brandts B, Meyer zu Heringdorf D, et al. Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1- phosphate. J Physiol. 1995;489:701-707. (Pubitemid 26016920)
8. Nakajima N, Cavalli AL, Biral D, et al. Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate. Eur J Biochem. 2000;267:5679-5686. (Pubitemid 30706934)
9. Mazurais D, Robert P, Gout B, et al. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem. 2002;50:661-670. (Pubitemid 34437559)
10. Zondag GC, Postma FR, Etten IV, et al. Sphingosine 1-phosphate signalling through the G-protein-coupled receptor Edg-1. Biochem J. 1998; 330:605-609.
11. Okamoto H, Takuwa N, Gonda K, et al. EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition. J Biol Chem. 1998;273:27104-27110. (Pubitemid 28500416)
12. Kon J, Sato K,Watanable T, et al. Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells. J Biol Chem. 1999;274:23940-23947. (Pubitemid 129528435)
13. Zhang J, Honbo N, Goetzl EJ, et al. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol. 2007;293:H3150-H3158. (Pubitemid 350106541)
14. Churchill E, Budas G, Vallentin A, et al. PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol. 2008; 48:569-599.
15. Jin ZQ, Zhou HZ, Zhu P, et al. Cardioprotection mediated by sphingosine- 1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J PhysiolHeart Circ Physiol. 2002;282:H1970-H 1977.
16. Lecour S, Smith RM, Woodward B, et al. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol. 2002;34:509-518.
17. Graeler MH, Kong Y, Karliner JS, et al. Protein kinase C epsilon dependence of the recovery from down-regulation of S1P1 G protein-coupled receptors of T lymphocytes. J Biol Chem. 2003;278:27737-27741. (Pubitemid 36899963)
18. Yue TL, Wang C, Gu JL, et al. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res. 2000;86:692-699. (Pubitemid 30208438)
19. Lips DJ, Bueno OF, Wilkins BJ, et al. MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation. 2004;109: 1938-1941.
20. Hausenloy DJ, Tsang A, Mocanu M, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971-H976. (Pubitemid 40139686)
21. Pesse B, Levrand S, Feihl F, et al. Peroxynitrite activates ERK via Raf-1 and MEK, independently from EGF receptor and p21Ras in H9C2 cardiomyocytes. J Mol Cell Cardiol. 2005;38:765-775. (Pubitemid 40591741)
22. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, et al. Preservation of baseline hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem 2004;279:3596-3604. (Pubitemid 38140600)
23. Zhou YY, Wang SQ, Zhu WZ, et al. Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. Am J Physiol Heart Circ Physiol. 2000;279:H429-H436.
24. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115:84-105. (Pubitemid 46990553)
25. Davis MD, Clemens JJ, Macdonald TL, et al. Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005;280:9833-9841.
26. Siehler S, Manning DR. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim Biophys Acta. 2002;1582:94-99. (Pubitemid 34634116)
27. Jin ZQ, Zhang J, Huang Y, et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury. Cardiovasc Res. 2007;76:41-50. (Pubitemid 47362044)
28. Means CK, Xiao CY, Li Z, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2007;292: H2944-H2951. (Pubitemid 47084545)
29. 1 receptor localization confers selectivity for Gi mediated cAMP and contractile responses. J Biol Chem. 2008;283:11954-11963.
30. Tao R, Zhang J, Vessey DA, et al. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res. 2007;74:56-63. (Pubitemid 46366955)
31. Karliner JS, Honbo N, Epstein CJ, et al. Neonatal mouse cardiac myocytes exhibit cardioprotection induced by hypoxic and pharmacologic preconditioning and by transgenic overexpression of human Cu/Zn superoxide dismutase. J Mol Cell Cardiol. 2000;32:1779-1786. (Pubitemid 30809626)
32. Duan HF, Wang H, Yi J, et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther. 2007;18:1119-1128. (Pubitemid 350114687)
33. Kim M, Kim M, Kim N, et al. Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1- phosphate-dependent pathways. Am J Physiol Renal Physiol. 2007;293: F1827-F1835. (Pubitemid 350179608)
34. Theilmeier G, Schmidt C, Hermann J, et al. High density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation. 2006;114:1403-1409. (Pubitemid 44454560)
35. Xin C, Ren S, Pfeilschifter J, et al. Heterologous desensitization of the sphingosine-1-phosphate receptors by purinoceptor activation in renal mesangial cells. Br J Pharmacol. 2004;143:581-589. (Pubitemid 39524275)
36. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007;282:9082-9089. (Pubitemid 47093504)
37. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004;18: 551-553.
38. Jo E, Sanna MG, Gonzalez-Cabrera PJ, et al. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005;12:703-715. (Pubitemid 43142048)
39. Liu CH, Thangada S, Lee MJ, et al. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999;10:1179-1190. (Pubitemid 29193739)
40. Igarashi J, Michel T. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. J Biol Chem. 2000;275:32363-32370.
41. Kohno T, Wasa A, Igarashi Y. N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization. FASEB J. 2002;16:983-992. (Pubitemid 34753504)
42. Gonzalez-Cabrera PJ, Hla T, Rosen H, et al. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem. 2007;282:7254-7264. (Pubitemid 47093659)
43. Okazaki M, Kreisel F, Richardson SB, et al. Sphingosine 1-phosphate inhibits ischemia reperfusion injury following experimental lung transplantation. Am J Transplant. 2007;7:751-758. (Pubitemid 46481193)
44. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290:F1516-F1524. (Pubitemid 43830779)
45. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxiareoxygenation injury. Am J Physiol Cell Physiol. 2002;282:C227-C241. (Pubitemid 34663181)
46. Germack R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 2005;39:429-442. (Pubitemid 41133729)
47. Kubasiak LA, Hernandez OM, Bishopric NH, et al. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A. 2002;99:12825-12830.
48. Das A, Lei X, Kukreja RC. Phosphodiesterase-5 inhibitor silendafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem. 2005;280:12944-12955. (Pubitemid 40491117)
49. Skyschally A, Schulz R, Heusch G. Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. Herz. 2008; 33:88-100.
50. Andreadou I, Iliodromitis EK, Koufaki M, et al. Pharmacological pre- and post- conditioning agents: reperfusion-injury of the heart revisited. Mini Rev Med Chem. 2008;8:952-959.
51. Vessey DA, Li L, Kelley M, et al. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun. 2008;375:425-429.
52. Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation. 2008;117:1037-1044.
53. Tsukada YT, Sanna MG, Rosen H, et al. S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J Cardiovasc Phamacol. 2007;50: 660-669. (Pubitemid 350307036)
54. Yeh CC, Li H, Malhotra D, et al. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009;296:H1193-H1199.
55. Okajima F. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an antiatherogenic mediator? Biochim Biophys Acta. 2002;1582l:132-137. (Pubitemid 34634121)
56. Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352:809-815. (Pubitemid 32015038)
57. Dalla Libera L, Sabbadini R, Renken C, et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-a and sphingosine. J Mol Cell Cardiol. 2001;33:1871-1878. (Pubitemid 32977139)
58. Deutschman DH, Carstens JS, Klepper RL, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J. 2003;146:62-68. (Pubitemid 36851301)
59. Berdyshev EV, Gorshkova IA, Garcia JGN, et al. Quantitative analysis of sphingoid base-1-phosphates as bisacetylated derivatives by liquid chromatography-tandem mass spectrometry. Anal Biochem. 2005;339: 129-136. (Pubitemid 40342687)
60. Schwab SR, Pereira JP, Matlobian M, et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309:1735-1739.